Emergency Preparedness and Response

About MCMi

MCMi logo – four diamond shapes with radiological and biohazard symbols, globe and test tubeThe Medical Countermeasures Initiative (MCMi) is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response, led by the Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist.

FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure.

Together with U.S. government partners through the Department of Health and Human Services Public Health Emergency Medical Countermeasures Enterprise, FDA helps define and prioritize requirements for MCMs in public health emergencies. This includes coordinating research, setting deployment and use strategies, and facilitating access to MCMs.

Learn more about MCMi's history

View FDA Strategic Priority 2.5 "Advance Medical Countermeasures and Emergency Preparedness" 

Full report: FDA Strategic Priorities 2011-2015

Page Last Updated: 01/23/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.